T-cell therapy for cancer

Immunotherapy

Volumn 4, Issue 4, 2012, Pages 347-350

  Barrett, John ^a   Bollard, Catherine M ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

adoptive transfer; cytotoxic T cells; graft versus leukemia

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 15; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRUS; ADENOVIRUS INFECTION; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DENDRITIC CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOTHERAPY; LEUKEMIA REMISSION; LYMPHOMA; MEMORY CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH17 CELL; VACCINATION;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 84860190342     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.12     Document Type: Review

References (40)

1. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl Med. 3, 95ra73 (2011).
2. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239 (2008).
3. Pule MA, Savoldo B, Myers GD et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264-1270 (2008).
4. Bollard CM, Gottschalk S, Leen AM et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110, 2838-2845 (2007). (Pubitemid 350006936)
5. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006). (Pubitemid 44547756)
6. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
7. Falkenburg JH, Heslop HE, Barrett AJ. T cell therapy in allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 14, 136-141 (2008). (Pubitemid 350286852)
8. Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, 236-24 2 (20 08).
9. Barrett J. Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment. Curr. Opin Immunol. 18, 592-598 (2006). (Pubitemid 44322034)
10. Vera JF, Brenner LJ, Gerdemann U et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J. Immunother. 33, 305-315 (2010).
11. Molldrem J, Riddell S. Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation. Cancer Treat. Res. 144, 187-208 (2009).
12. Kolb HJ, Mittermuller J, Clemm CH et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462-2465 (1990).
13. + minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Clin. Invest. 96, 877-883 (1996).
14. Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925-935 (2010).
15. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodefcient humans by the adoptive transfer of T cell clones. Science 257, 238-241 (1992).
16. Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infltrating lymphocytes modifed by retroviral gene transduction. N. Engl. J.Med. 323, 570-578 (1990). (Pubitemid 20260084)
17. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13, 545-586 (1995).
18. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357 (2005). (Pubitemid 46218728)
19. + T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294-305 (2008).
20. Gattinoni L, Lugli E, Ji Y et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-1297 (2011).
21. Muranski P, Borman ZA, Kerkar SP et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35, 972-985 (2011).
22. Turtle CJ, Delrow J, Joslyn RC et al. Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8alpha semi-invariant T cells. Blood 118, 2752-2762 (2011).
23. Kennedy-Nasser AA, Hanley P, Bollard CM. Hodgkin disease and the role of the immune system. Pediatr. Hematol. Oncol. 28, 176-186 (2 011).
24. El-Bietar J, Bollard C. T-cell therapies for Epstein-Barr virus-associated lymphomas. Pediatr. Hematol. Oncol. 28, 627-639 (2011).
25. Gottschalk S, Ng CYC, Smith CA et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 97, 835-843 (2001). (Pubitemid 32154261)
26. Gerdemann U, Katari U, Christin AS et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol. Ther. 19, 2258-2268 (2011).
27. Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12, 116 0-116 6 (2 0 0 6).
28. Peggs KS, Verfuerth S, Chow C et al. Adoptive cellular therapy for cytomegalovirus following allogeneic stem cell transplantation: toxicity and effcacy. Blood 104, Abstract 191 (2005).
29. Hanley PJ, Cruz CR, Savoldo B et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114, 1958-1967 (20 0 9).
30. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99, 3179-3187 (2002). (Pubitemid 34525296)
31. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102 (2010).
32. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial. Mol. Ther. 18, 666-668 (2010).
33. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modifed T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011).
34. Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modifed autologous CD20-specific T cells. Blood 112, 2261-2271 (2008).
35. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
36. Dunleavy K, Bollard CM. Sobering realities of surviving Hodgkin lymphoma. Blood 1 1 7, 1772-1773 (2011).
37. Cruz CR, Gerdemann U, Leen AM et al. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin. Cancer Res. 17, 7058-7066 (2011).
38. Craddock C. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies. Cytotherapy 13, 516-517 (2011).
39. Hoyos V, Savoldo B, Quintarelli C et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2 4, 116 0-117 0 (2 010).
40. Huang RR, Jalil J, Economou JS et al. CTLA4 blockade induces frequent tumor infltration by activated lymphocytes regardless of clinical responses in humans. Clin. Cancer Res. 17, 4101-4109 (2011).